HALBERT DAVID D 4

What Happened

• David D. Halbert — Founder, Chairman and CEO of Caris Life Sciences (10% owner) — had 40,712 shares withheld on May 15, 2026 to cover tax obligations tied to the vesting/settlement of RSUs. The shares were recorded at $15.25 each, totaling approximately $620,858. This was a withholding/tax-payment disposition, not an open-market sale.

Key Details

• Transaction date: 2026-05-15; Filing date: 2026-05-18 (timely filing).
• Price: $15.25 per share; Shares withheld/disposed: 40,712; Value ≈ $620,858.
• Reported beneficial ownership (per filing footnote): 121,025,002 shares held across related entities (Caris Halbert, L.P.; ADAPT I Ltd.; Carisome I, L.P.; Caris Investment II & III Ltd.; Halbert Family Capital, LLC).
• Footnotes: F1 — shares were withheld to pay taxes on RSU vesting/settlement. F3 — Mr. Halbert is managing member/trustee with voting/investment power over the entities listed but disclaims beneficial ownership except to the extent of his pecuniary interest.
• Transaction code: F (tax withholding on vested awards), not a market purchase or sale (no 10b5-1 plan or late filing noted).

Context

• This is a routine tax-withholding event common when restricted stock units vest. The company retained/withheld shares to satisfy tax obligations (a cashless-type settlement of tax), so it should not be interpreted the same way as an outright open-market sale or a purchase. As a 10% owner with holdings reported via related entities, Mr. Halbert’s filing reflects institutional/control relationships rather than simple personal trades.